Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/18872
Título
Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19
Autor(es)
Ramos Rincón, José Manuel | Pérez-Belmonte, Luis M. | Carrasco-Sánchez, Francisco Javier | Jansen-Chaparro, Sergio | De-Sousa-Baena, Mercedes | Bueno-Fonseca, José | Pérez-Aguilar, Maria | Arévalo-Cañas, Coral | Bacete Cebrian, Marta | Méndez Bailón, Manuel | Fiteni Mera, Isabel | González García, Andrés | Navarro Romero, Francisco | Tuñón de Almeida, Carlota | Muñiz Nicolás, Gemma | Gonzáez Noya, Amara | Hernández Milian, Almudena | García-García, Gema-María | Alcalá-Pedrajas, José-Nicolás | Herrero García, Virginia | Corral-Gudino, Luis | Comas Casanova, Pere | Meijide Mírguez, Héctor | Casas Rojo, José Manuel | Gómez Huelgas, Ricardo | SEMI-COVID-19 Network
Fecha de publicación
2021
Idioma
Inglés
Tipo de documento
research article
Resumen
Background: The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ?80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. Method: We conducted a nationwide, multicenter, observational study in patients ?80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Results: Of the 2 763 patients ?80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. Conclusions: We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.
Palabras clave
MESH
Aged, 80 and over | Angiotensin Receptor Antagonists | COVID-19 | Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Dipeptidyl-Peptidase IV Inhibitors | Female | Hospital Mortality | Hospitalization | Humans | Hypoglycemic Agents | Male | SARS-CoV-2
DOI
Aparece en las colecciones
Acceso a texto completo